Kornimate/medical-research-clean huggingface dataset:
efficacy of two injection techniques on success rate of inferior alveolar nerve anesthesia

Conditions: Failed Mechanical Induction

Summary: forty healthy patients with including criteria who failed to infra alveolar nerve block injection (without lip numbness) have been randomly divided into two groups on a random basis and have received gow-gates or another inferior alveolar nerve block injection. endodontic access cavity preparation has been initiated after complete anesthesia. if patients felt any pain during the steps of caries or dentin removal, endodontic access cavity preparation or canal working length determination, treatment has been stopped and their pain has been measured by heft parker 170 mm visual analog scale (zero as no pain and 170 as maximum pain ).the data has been analyzed by mann-u-whitney and chi- square tests.

the aim of this study was to assess the efficacy of gow-gates and inferior alveolar nerve block on success rate of anesthesia in patients with irreversible pulpitis. in this prospective, randomized, double-blind study , forty healthy patients with symptomatic irreversible pulpitis and including criteria who failed to infra alveolar nerve block injection (without lip numbness) have been randomly divided into two groups on a random basis and have received gow-gates or another inferior alveolar nerve block injection. their pain has been evaluated by electric pulp tester every 5 minutes for two times. endodontic access cavity preparation has been initiated after complete anesthesia. if patients felt any pain during the steps of caries or dentin removal, endodontic access cavity preparation or canal working length determination, treatment has been stopped and their pain has been measured by heft parker 170 mm visual analog scale (zero as no pain and 170 as maximum pain ). the patients have been instructed to rate any pain during each of the mentioned steps. the data have been analyzed by mann-u-whitney and chi- square tests.

Eligibility criteria:
inclusion criteria: * patients with symptomatic irreversible pulpitis ( visual analog scale ≥ 54) in one mandibular molar who need root canal treatment * without systemic diseases * non smoking * non analgesic/sedative or any medicine consumption * non pregnant * non breast feeding * the patients who received one conventional inferior alveolar nerve block and their block was failed ( without lip numbness) exclusion criteria:
ani parasympathetic monitoring in neurosurgery

Conditions: Bradycardia

Summary: surgery of large cerebellopontine angle (cpa) tumors (\>2 x 2 cm diameter), with compression of the pons exposes the patient to inadvertent parasympathetic nerve stimulation (ipns) leading to bradycardia and asystole. the analgesia nociception index (ani) monitor assesses the balance between analgesia and nociception through the detection of parasympathetic tone. ani \>80 generally denotes excessive analgesia (ea). the main objective of this study was to determine whether ani values for ipns are different or the same as ani values for ea. this study also aims at calculating the number of patients with ipns and ea during surgery of large cpa tumours.

bradycardia and asystole are potential life threatning complications during surgery of large cerebellopontine angle (cpa) tumors (\>2 x 2 cm diameter), with compression of the pons.the incidence of such complications are unknown. one of the plausible mechanisms is inadvertent parasympathetic nerve stimulation (ipns) due to the proximity of this cranial nerve to the cpa tumor. monitoring parasympathetic nerve activity may provide further insight to the implication of this cranial nerve in the cardiac complications observed during surgery of large cpa tumors. the analgesia nociception index (ani) monitor assesses the balance between analgesia and nociception through the detection of parasympathetic tone. despite the abundant clinical reports about this index, to the knowledge of the investigators, only a few studies have been published in the neurological setting. moreover, there are no data reporting the parasympathetic profile (measured by the ani monitor) in situations of ipns and ea. are these profiles the same or different? such is the main question this study thrives to answer. understanding the behavior of parasympathetic nerve activity in this context could help provide the appropriate management strategy. in order to answer this question, participants undergoing elective large cpa tumor surgery were included in this prospective observational study. standard cardiorespiratory monitoring including heart rate (hr) was done. target-controlled anesthesia with propofol and remifentanil was guided by a bispectral index of 30-40 and an ani of 50-70 respectively. data was continuously recorded with event markers at the onset of bradycardia (hr \ 80 with remifentanil site effect \> 6 ng.ml-1 (defined as excessive analgesia).

Eligibility criteria:
inclusion criteria: * patients undergoing elective surgery of large cerebellopontine angle tumors exclusion criteria: * age below 18yr * arrhythmia * preoperative use of vagolytics, β-blockers and clonidine.

Keywords: analgesia nociception index parasympathetic nerve stimulation excessive analgesia
migration and functional outcome of delta xtend reverse shoulder lateralized glenosphere line extension system

Conditions: Rotator Cuff Arthropathy or Degeneration of the Glenohumeral Joint with Severe Posterior Wear

Summary: this is a randomized controlled trial comparing the delta xtend reverse shoulder system lateralized glenosphere line extension (intervention group) with the standard delta xtend reverse shoulder system (control group). all danish citizens with rotator cuff arthropathy or degeneration of the glenohumeral joint with severe posterior wear indicating a reverse total shoulder arthroplasty referred to the orthopedic department at herlev and gentofte hospital, copenhagen university hospital will be considered for participation in the trial. the following exclude from participation in the study: below 50 years of age; cognitive or linguistic impairment; insufficient glenoid bone stock; previous fracture in the upper extremities; autoimmune mediated inflammatory arthritis.a total of 122 patients will be included of which 56 will be part of the roentgen radiostereometric analysis. this will allow a maximum of 20% drop out. the primary outcome is magnitude and pattern of migration of the glenoid component and functional outcome by western ontario osteoarthritis of the shoulder index (woos score). the secondary outcomes are position of arthroplasty, loosening, inferior scapular notching, patient-reported outcomes, functional outcome, readmission, complications, revisions, changes in bone mineral density of the proximal humerus assessed by duel energy x-ray absorptiometry and economy (cost utility analysis). the patients are examined before the operation and 1 week and 3, 6, 12 and 24 months after the operation.


Eligibility criteria:
inclusion criteria: 1. rotator cuff arthropathy defined as degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon 2. degeneration of the glenohumeral joint with intact rotator cuff function but severe posterior wear of the glenoid (\>20 degrees posterior wear) 3. insufficient effect of non-surgical treatment with symptoms severe enough to justify shoulder arthroplasty. 4. asa (american society of anesthesiology) score 1-3, physically fit for surgery and rehabilitation exclusion criteria: 1. below 50 years of age 2. cognitive or linguistic impairment 3. insufficient glenoid bone-stock 4. previous fracture in the upper extremities 5. patients with autoimmune mediated inflammatory arthritis 6. glenoid border medial to the medial border of the coracoid on a true ap radiograph
folfoxiri as primary treatment for locally advanced pancreatic cancer

Conditions: Pancreatic Carcinoma Stage III

Summary: the study is conducted as a monocentric prospective phase ii trial. patients with unresectable stage iii locally advanced pancreatic cancer (defined for extended encasement of superior mesenteric artery/celiac axis/hepatic artery or for combined venous and arterial involvement or for unreconstructible venous encasement), ecog ps 0-1 and age 18-75 are eligible. after multidisciplinary evaluation of resectability, treatment with folfoxiri is provided for a maximum of 12 cycles with multidisciplinary evaluation of disease status every 4 cycle. in case of tumors have deemed resectable surgery is considered. in case tumors remain unresectable, radiotherapy is evaluated after the end of chemotherapy. primary objective of the study is the rate of patients who become resectable and undergo radical surgical resection after chemotherapy. secondary objectives are: response rate, progression-free survival, overall survival, toxicity.


Eligibility criteria:
inclusion criteria: * stage iii unresectable pancreatic cancer defined for: * extended encasement of superior mesenteric artery or celiac axis/hepatic artery * both arterial and venous (portal vein/superior mesenteric vein) encasement * unreconstructible vessel encasement * ecog performance status 0-1 * age 18-75 * adequate liver, renal and bone marrow function exclusion criteria: * evidence of distant metastases * cardiovascular diseases * contraindications to studied drugs
treatment for advanced b-cell lymphoma

Conditions: Diffuse Large Cell Lymphoma; Burkitt's Lymphoma; High Grade B-cell Lymphoma

Summary: to safely reduce the burden of therapy in children, adolescents and young adults with mature b-nhl by reducing the number of intrathecal (it) injections by the introduction of it liposomal cytarabine (l-ara-c, \[depocyt®\]) and reducing the dose of anthracycline (doxorubicin) in good risk patients with the addition of rituximab to the fab chemotherapy backbone (immunochemotherapy).


Eligibility criteria:
inclusion criteria: * newly diagnosed mature b-lineage (cd20 positive) leukemia/lymphoma * 1. diffuse large cell lymphoma (not primary mediastinal b-cell lymphoma) -2. burkitt's lymphoma * 3. high grade b-cell lymphoma---burkitt's like. b-cell anaplastic large cell ki 1 positive lymphomas, primary mediastinal b-cell lymphoma (pmbl), and b-lymphoblastic lymphomas are ineligible. no previous chemotherapy. patients who have received emergency irradiation and/or steroid therapy will be eligible only if started on protocol therapy not more than 72 hours from the start of radiotherapy or steroids. bone marrow and cerebrospinal fluid must be obtained before steroids are given for patient to be eligible for the study. exclusion criteria: * patients with newly diagnosed group a (low risk) lymphoma. patients with group b (intermediate risk) if classified as murphy stage iii/iv and diagnostic ldh \> 2 xuln and patients with primary mediastinal b-cell lymphoma (pmbl). * patients who have received any steroids in the week prior to diagnosis except as stated in section 4.1.4 of the protocol. * no congenital or acquired immune deficiency. these patients are excluded due to the expected intense immunosuppression, increased risk of opportunistic infections, and higher expected septic death rate in this subgroup of patients with this proposed therapy. * no prior solid organ transplantation. * patients with previous malignancies that have been treated with systemic chemotherapy with alkylator or anthracycline therapy. the latter group of patients are excluded due to an expected increase in late effects (eg. late cardiac toxicity, secondary malignancies, sterility, etc.). * patients with known g6pd deficiency are not eligible for rasburicase therapy. patients with g6pd deficiency should be treated with alkalinization, iv hydration and po and/or iv allopurinol during the reduction phase (cop). 4.2.6 patients with serious (sepsis, pneumonia, etc..) proven or suspected infections at diagnosis will be excluded. 4.2.7 pregnancy or breast-feeding: no information is available regarding human fetal or teratogenic toxicities. pregnancy tests must be obtained in girls who are post-menarchal. males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.

Keywords: pediatric lymphoma (not primary mediastinal b-cell lymphoma) b-cell---burkitt's like rituximab liposomal ara-c
pre and postoperative gait analysis of randomized patient to 2 different cement fixation methods

Conditions: Gait Analysis; Hip Arthritis; Total Hip Arthroplasty

Summary: the primary goal of total hip replacement (thr) surgery in the treatment of hip osteoarthritis is to reduce pain and restore hip function in order to increase patient mobility and quality of life. two different cement fixation methods are used in order to insert thr implants. this will be done before and after surgery in 2 groups randomized to either of 2 cement fixation methods. gait analysis preoperative and 2 year after surgery.

the primary goal of total hip replacement (thr) surgery in the treatment of hip osteoarthritis is to reduce pain and restore hip function in order to increase patient mobility and quality of life. patients with radiological signs of osteoarthritis of the hip, hip pain and functional disability may be treated with insertion of a tha. two different fixation methods are used in order to insert thr implants. cemented fixation using bone cement, polymethyl methacrylate (pmma) is the most commonly used fixation method in sweden. a new bone cement, refobacin®, already marketed in germany is planned to be introduced in sweden in late 2018. the hospital is also equipped with a modern gait laboratory were the functional gait performance can be evaluated. this will be done before and after surgery in 2 groups randomized to either of 2 cement fixation methods. the subjects will undergo gait analysis befor and 2 year after surgery.

Eligibility criteria:
inclusion criteria: * hip arthritis exclusion criteria: * no hip arthritis
3d foot scanner reliability for footwear fit and design

Conditions: Diabetes Complications

Summary: the investigators will carry out a proof-of-concept study in 20 adult healthy male and female volunteers in order to: assess a 3d foot scanner's reliability. specifically, the investigators will assess its variability during repeated foot scans of the same subject's foot. three repeated foot scans will be carried out by two different examiners to measure intrarater and interrater reliability (intraclass correlation coefficient

evidence of reliability is essential for use of a 3d foot scanner in diabetes footwear fit evaluation and orthopaedic footwear design. the investigators will carry out a proof-of-concept study in 20 healthy adult male and female volunteers in order to: assess the 3d foot scanner's reliability. specifically, the investigators will assess its variability during three repeated foot scans of the same subject's foot. three half weightbearing foot scans will be carried out by two different examiners to measure intrarater and interrater reliability (intraclass correlation coefficient). the investigators will carry out a proof-of-concept study in 20 healthy adult male and female volunteers (10 each) in order to assess the elinvision 3d foot scanner's (i) intra-rater reliability through repeated foot scans (3 times each) and (ii) inter-rater reliability of these scans as carried out by two independent examiners whilst participants are half weightbearing to establish adequate reliability (0.80+ icc) for use in subsequent diabetes footwear fit assessment and orthopaedic footwear design and manufacture.

Eligibility criteria:
inclusion criteria: * healthy men and women aged 18 years or over * able to walk unaided * able to walk up steps (the 3d scanner requires a small step on to the device to enter the correct position for measurement) * willingness and capacity to participate in the study and to sign the informed consent form exclusion criteria: * diabetes mellitus diagnosis * inability to ambulate independently without walking aids * no obvious foot deformities * no history of foot surgery * no pain, injuries or medical conditions affecting the legs or lower back * any issues around balance (participants must remain standing in position for the approximately fifteen seconds required to obtain the 3d scan of their feet) * health conditions that impact foot morphology

Keywords: 3d foot scan 3d foot scanner foot scan reliability repeatability
primary dynamization versus standard interlocking intramedullary nail in treatment of tibial shaft fractures in adults

Conditions: Tibial Shaft Fractures

Summary: fracture shfat tibia in adults treated by interlocking intramedullary nail by primary dynamic versus standard ways


Eligibility criteria:
inclusion criteria: * adult patients (18-50) fractures with mid shaft or distal shaft tibial fracture ao type a1, a2 and a3 and minimal soft tisuue damage exclusion criteria: * patients with comminuted fractures , old age more than 50 years , sclerotic bone , osteoporosis, osteopetrosis and bone deformity
l5-s1 disc fate in thoracolumbar arthrodesis stopping at l5

Conditions: Spinal Deformity

Summary: spinal deformity in adults is one of the most frequently treated pathologies in spinal surgery. their surgical treatment remains a challenge. in particular, the choice of the borderline vertebrae for thoracolumbar fusion correction remains controversial, including the choice between an instrumented last vertebra at l5 and an arthrodesis extending to the pelvis. studies and meta-analyses show that an ilio-sacral socket provides better correction of pelvic parameters and avoids the development of distal junctional syndrome. on the other hand, there is more proximal junctional syndrome in patients fixed to the sacrum, and the sacral socket exposes patients to the risk of pseudarthrosis of the l5-s1 level and failure of the fixation hardware. moreover, although this factor is not described in the studies, it would seem that an ilio-sacral socket is more stiffening. overall, no study has shown a statistically significant difference in clinical scores between patients whose last instrumented vertebra is l5 and those with pelvic fixation. one of the theoretical risks of an extended fixation with a proximal thoracic grasp is to observe a premature disc degeneration of the l5-s1 disc since it would be subjected to more stress. this degeneration could be the cause of distal junctional syndrome and lumbo-radiculalgia due to inflammatory disc disease and disco-radicular impingement. however, to investigator's knowledge, no clinical study has yet investigated the medium- and long-term fate of the l5-s1 disc in patients with extended fusion correction of a thoracic vertebra to l5. investigator's team has sometimes favored a final instrumented vertebra at l5 when possible, i.e., when the l5-s1 disc was considered to be minimally or not degenerative and when its horizontality could be obtained after correction of the underlying curvature. investigators therefore have a cohort of patients who have undergone this technique. the usual follow-up of these patients includes a consultation appointment every 2 to 5 years and a control mri at a distance of more than 5 years: investigators thus have a control mri and the clinical score of the patients. investigator's objective is to determine whether there is degeneration of the l5-s1 disc, using mri imaging data, which has never been published to investigator's knowledge.


Eligibility criteria:
inclusion criteria: * patient whose age is ≥ 18 years * spinal fixation extended from the thorax to l5, * performed between 2007 (15 years of recoil and beginning of systematic preoperative mri) and 2017 (5 years of recoil minimum) * french speaking patient exclusion criteria: * neuromuscular scoliosis * indication of fixation for fracture of ankylosed spine (impossibility of analyzing the l5-s1 disc) * contraindication to the realization of an mri except if the patient has been operated on for a complementary fixation of l5-s1 in the aftermath * patient under guardianship or curatorship (unless consent is provided for this purpose) * patient deprived of liberty * patients who oppose participation in the study
the relationship between urinary incontinence and motor symptoms

Conditions: Stroke; Urinary Incontinence; Motor Skills Disorders

Summary: there is no study in the literature examining the relationship between urinary incontinence and motor symptoms in individuals with stroke. the aim of this study is to determine the relationship between urinary incontinence and spasticity, balance and walking, which negatively affect quality of life and functional performance after stroke.

evaluation parameters used in the study: modified rankin score 24 hours pad test tinetti balance and gait scale modified ashworth scale danish prostatic symptom score

Eligibility criteria:
inclusion criteria: * being 18 years old, having a stroke history of at least 3 months, having had only one stroke, scoring between 0-2 points according to mrs, being able to stand and walk independently or with a walking aid, being able to speak turkish. exclusion criteria: * those with incomprehensible speech disorders, * those who have additional neurological diseases other than stroke, * orthopedic, cardiovascular, etc., which may cause balance disorders. those with illnesses, * those who are pregnant, * those with vision and hearing loss

Keywords: stroke urinary incontinence spasticity balance gait
a phase 1 study evaluating safety, tolerability, and pharmacokinetics of vx-407 in healthy participants

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Summary: the purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of vx-407 in healthy participants.

this clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (that is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(a) of the public health service act and 42 cfr 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the public health service act or 42 cfr 11.24 and 11.44.).

Eligibility criteria:
key inclusion criteria: * body mass index (bmi) of 18.0 to 32.0 kilogram per meter square (kg/m\^2) * a total body weight of greater than (\>) 50 kg * nonsmoker or ex-smoker for at least 3 months before screening key exclusion criteria: * history of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug * any condition possibly affecting drug absorption other protocol defined inclusion/exclusion criteria will apply.
surgical treatments of tricuspid valve regurgitation after cardiac surgery

Conditions: Tricuspid Valve Regurgitation; Complications, Longterm Outcome

Summary: this study aims to present our center's experience in managing postoperative tricuspid valve regurgitation over the past 25years and to analyze the outcomes of these surgical treatments.


Eligibility criteria:
inclusion criteria:patients who underwent surgical treatment from 1999 to 2023 for tricuspid valve disease following cardiac surgery exclusion criteria: age \<16，severe tricuspid regurgitation secondary to primary pulmonary hypertension, and those with substantial missing case data.

Keywords: tricuspid valve regurgitation; technique advances; complications